Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 9.26
- Piotroski Score 7.00
- Grade Buy
- Symbol (ROIV)
- Company Roivant Sciences Ltd.
- Price $11.49
- Changes Percentage (-0.35%)
- Change -$0.04
- Day Low $11.40
- Day High $11.55
- Year High $13.06
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/11/2024
- Fiscal Year End N/A
- Average Stock Price Target $17.00
- High Stock Price Target $20.00
- Low Stock Price Target $12.50
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $5.23
- Trailing P/E Ratio 2
- Forward P/E Ratio 2
- P/E Growth 2
- Net Income $4.35 B
Income Statement
Quarterly
Annual
Latest News of ROIV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Roivant Sciences (ROIV): High-Growth UK Stock with Innovative Drug Development Model
Roivant Sciences (NASDAQ:ROIV) is a UK high-growth stock, known for its innovative biopharmaceutical developments. The company recently made a strategic sale of its subsidiary to Organon & Co., boosti...
By Yahoo! Finance | 2 weeks ago -
Roivant Sciences Ltd. (ROIV): Among the Most Promising Mid-Cap Stocks According to Hedge Funds
Roivant Sciences Ltd. (NASDAQ:ROIV) is ranked as the top mid-cap stock by hedge funds, showing impressive growth. With a focus on drug development and positive trial results, the company's expansion s...
By Yahoo! Finance | 3 weeks ago -
Is Roivant Sciences Ltd. (ROIV) a Strong Buy Amid Positive Clinical Trials and Strategic Partnerships?
A list of top small company stocks to invest in was recently published, analyzing Roivant Sciences Ltd. against others. With the Fed's interest rate cuts impacting the market, small-cap stocks are see...
By Yahoo! Finance | 1 month ago
